New Treatment Approach for Advanced Coronary Artery Disease Leads to Improved Outcomes
Study outlines better way to identify where stents are necessary
Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure the severity of artery blockages can lead to significantly improved outcomes after percutaneous coronary intervention (PCI), according to a new study done in collaboration with Mount Sinai faculty.
This research, which is the first to analyze QFR and its associated clinical outcomes, may lead to widespread adoption of QFR as an alternative to angiography or pressure wires to measure the severity of blockages, or lesions, in patients with coronary artery disease. The study results were announced on Thursday, November 4, as a late-breaking clinical trial at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2021), and simultaneously published in The Lancet.
“For the first time we have clinical validation that lesion selection with this method improves outcomes for patients with coronary artery disease undergoing stent treatment,” says senior author Gregg W. Stone, MD, Director of Academic Affairs for Mount Sinai Health System and Professor of Medicine (Cardiology), and Population Health and Policy, at the Icahn School of Medicine at Mount Sinai. “By avoiding the time, complications, and extra resources required to measure lesion severity using a pressure wire, this simpler technique should serve to greatly expand the use of physiology in patients undergoing cardiac catheterization procedures.”
Patients with coronary artery disease—plaque build-up inside the arteries that leads to chest pain, shortness of breath, and heart attack—often undergo PCI, a non-surgical procedure in which interventional cardiologists use a catheter to place stents in the blocked coronary arteries to restore blood flow.
Most doctors depend on angiography (X-rays of the coronary arteries) to determine which arteries have the most severe blockages, and use that visual assessment to decide which arteries to treat. This method is not perfect: some blockages may look more or less severe than they actually are and doctors can’t precisely tell from the angiogram alone which blockages are most seriously affecting blood flow. Outcomes can be improved if lesions to stent are selected using a pressure wire to identify which are obstructing blood flow. But this measurement procedure takes time, can cause complications, and entails extra costs.
QFR technology uses 3D artery reconstruction and measurement of blood flow velocity that gives precise measurements of the pressure drop across a blockage, allowing doctors to make better decisions as to what arteries to stent during PCI.
To study how QFR impacts patient outcomes, researchers conducted a multi-center, randomized, blinded trial of 3,825 participants in China undergoing PCI between December 25, 2018, and January 19, 2020. Patients either had had a heart attack 72 hours prior, or had at least one coronary artery with one or more blockages that the angiogram measured as between 50 and 90 percent narrowed. Half of the patients underwent the standard angiography-guided procedure based on visual assessment, while the other half underwent the QFR-guided strategy.
In the QFR-guided group, doctors chose not to treat 375 vessels that were originally intended for PCI, compared to 100 in the angiography-guided group. The technology thus helped eliminate a greater number of unnecessary stents. In the QFR group, doctors also treated 85 vessels not originally intended for PCI compared to 28 in the angiography-guided group. The technology thus identified more obstructive lesions that wouldn’t have otherwise been treated.
As a result, patients in the QFR group had lower one-year rates of heart attack compared to the angiography-only group (65 patients vs. 109 patients) and a lesser chance of needing additional PCI (38 patients vs. 59 patients) with similar survival. At the one-year mark, 5.8 percent of patients treated with the QFR-guided PCI procedure had either died, had a heart attack, or needed repeat revascularization (stenting), compared to 8.8 percent of patients undergoing the standard angiography-guided PCI procedure, a 35 percent reduction. The researchers attributed these significant improvements in outcomes to QFR allowing doctors to choose the correct vessels for PCI and also avoid unnecessary procedures.
“The results from this large-scale blinded randomized trial are clinically meaningful, and similar to what would have been expected with pressure wire-based PCI guidance. Based on these findings, following regulatory approval I would anticipate QFR to be widely adopted by interventional cardiologists to improve outcomes for their patients.” said Dr. Stone.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.